Latest Pneumococcal vaccine Stories
Dramatic advance in understanding of how the body fights bacteria paves way for more effective vaccines.
DALLAS, November 3, 2010 /PRNewswire/ -- ReportsandReports announces it will carry European Vaccine Markets Research Report in its store. Browse the complete Report on: http://www.reportsnreports.com/Reports/38156-european-vaccine-markets.html Browse All Manufacturing & Construction Reports: http://www.reportsnreports.com/market-research/medical-devices/ Browse All Kalorama Research Reports at http://www.reportsnreports.com/publishers/kalorama-information/ The European...
Contrary to current thinking, the group of serotypes of Streptococcus pneumoniae responsible for most invasive pneumococcal disease worldwide is conserved across regions.
Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease.
The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the 2 years following the introduction of a vaccine to combat the disease.
NEW YORK, Aug.
A Johns Hopkins University scientist, whose team of researchers recently identified pneumonia, diarrhea, and malaria as the primary causes of death of 6 million of the world's poorest children, today called on leaders in donor and developing nations to take action to address the terrible death toll.
PHILADELPHIA, July 19 /PRNewswire-USNewswire/ -- A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.
James E. Connolly Committed to Accelerating the Development of New Vaccines to Prevent Tuberculosis ROCKVILLE, Md., July 1 /PRNewswire-USNewswire/ -- The Aeras Global TB Vaccine Foundation today announced that James E. Connolly has been named President and Chief Executive Officer.
Kaiser Permanente used electronic health records to study 84,000 men.